All of this chatter about atherectomy versus balloon/stent is moot.

The big problem with CSI is the sale model. They have over 100 sales and sales managers when the revenue justifies half that number.

The Diamondaback is an awesome tool for calcified lesions and has great potential for coronary arteries.

Cut the cost of sales and this company has great long term potential. Continue to try and ramrod marketing smoke and mirrors rhetoric in the worst recession in our memory down the throats of skeptical interventionalists and administrators and you will continue to see declining usage.